Lab
Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings was paid $53.17M by Medicaid between Jan 2018 and Dec 2024, across 198 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 25% of everything it billed.
33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
RESEARCH TRIANGLE PARK, NC 27709
RESEARCH TRIANGLE PARK, NC 27709
33aNPI1033196001assigned 12/29/2005
33bProvider typeClinical Medical Laboratory
28Total paid$53.17M
24GClaims555,582
24DCodes billed198
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in North Carolina
Rank by total paid#7 of 128
Median peer was paid$268K
This provider vs. median198×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,172 | $2.84M | |
| 2019 | 47,785 | $5.32M | |
| 2020 | 95,094 | $10.09M | |
| 2021 | 108,286 | $10.76M | |
| 2022 | 83,009 | $9.24M | |
| 2023 | 106,300 | $7.75M | |
| 2024incomplete | 96,936 | $7.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 25% | 163,570 | 152,158 | $13.50M |
| 81229 | 21% | 25,968 | 23,636 | $10.94M | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 15% | 10,381 | 10,336 | $8.24M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 9.6% | 47,551 | 46,323 | $5.09M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 6.4% | 18,625 | 18,509 | $3.38M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.1% | 34,716 | 34,468 | $2.18M |
| 88185 | 3.2% | 7,630 | 6,127 | $1.69M | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.7% | 9,202 | 9,137 | $905K |
| 88262 | 1.3% | 9,400 | 8,858 | $693K | |
| 88230 | 1.1% | 9,384 | 8,838 | $565K | |
| 88313 | <1% | 7,702 | 7,675 | $507K | |
| 86769 | <1% | 7,063 | 6,985 | $377K |
186 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,770 | $365K |
| 81206 | <1% | 6,484 | $360K | |
| 88342 | <1% | 3,747 | $349K | |
| 81374 | <1% | 5,075 | $331K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,259 | $316K |
| 81207 | <1% | 6,441 | $303K | |
| 81270 | <1% | 8,984 | $286K | |
| 88189 | <1% | 6,321 | $257K | |
| 88184 | <1% | 6,620 | $237K | |
| 81243 | <1% | 4,329 | $202K | |
| 88235 | <1% | 2,364 | $191K | |
| 88271 | <1% | 5,023 | $164K | |
| 81279 | <1% | 3,046 | $156K | |
| 88237 | <1% | 2,390 | $146K | |
| 81219 | <1% | 3,733 | $132K | |
| 81338 | <1% | 2,777 | $127K | |
| 88269 | <1% | 1,322 | $121K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 1,618 | $111K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 631 | $108K |
| 81401 | <1% | 1,309 | $88K | |
| 88275 | <1% | 2,290 | $81K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,482 | $75K |
| 88274 | <1% | 2,510 | $70K | |
| 81402 | <1% | 1,012 | $63K | |
| 88173 | <1% | 972 | $49K | |
| 81403 | <1% | 1,096 | $46K | |
| 88289 | <1% | 2,460 | $41K | |
| 88280 | <1% | 1,820 | $27K | |
| 88233 | <1% | 384 | $27K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 214 | $21K |
| 88285 | <1% | 1,814 | $20K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 61 | $20K |
| 81381 | <1% | 191 | $19K | |
| 88261 | <1% | 152 | $18K | |
| 81256 | <1% | 297 | $16K | |
| 81241 | <1% | 297 | $13K | |
| 82668 | <1% | 1,319 | $11K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 123 | $10K |
| 88360 | <1% | 27 | $8K | |
| 81327 | <1% | 457 | $7K | |
| 81200 | <1% | 151 | $7K | |
| 81242 | <1% | 106 | $5K | |
| 81260 | <1% | 149 | $5K | |
| 81377 | <1% | 27 | $4K | |
| 81291 | <1% | 96 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,961 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,829 | $4K |
| 82106 | <1% | 457 | $4K | |
| 83521 | <1% | 63 | $4K | |
| 81273 | <1% | 86 | $3K | |
| 81422 | <1% | 14 | $3K | |
| 81240 | <1% | 110 | $2K | |
| 81209 | <1% | 106 | $2K | |
| 83883 | <1% | 312 | $2K | |
| 88112 | <1% | 2,285 | $2K | |
| 81257 | <1% | 43 | $2K | |
| 82105 | <1% | 395 | $2K | |
| 86038 | <1% | 542 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,084 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,775 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,051 | $2K |
| 81290 | <1% | 38 | $2K | |
| 80053 | Comprehensive metabolic panel | <1% | 9,497 | $2K |
| 81330 | <1% | 38 | $2K | |
| 81251 | <1% | 38 | $1K | |
| 84410 | <1% | 25 | $1K | |
| 80061 | Lipid panel | <1% | 7,991 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,010 | $1K |
| 81210 | <1% | 16 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 185 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 160 | $917.69 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 973 | $678.14 |
| 85652 | <1% | 690 | $663.32 | |
| 82746 | <1% | 1,789 | $655.84 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,899 | $641.23 |
| 81255 | <1% | 13 | $511.03 | |
| 84439 | <1% | 2,631 | $463.67 | |
| 85027 | <1% | 1,337 | $436.28 | |
| 82607 | <1% | 2,332 | $415.05 | |
| 81329 | <1% | 37 | $411.70 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 176 | $347.06 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,821 | $334.15 |
| 82728 | <1% | 921 | $267.56 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 112 | $240.00 |
| 86480 | <1% | 196 | $238.35 | |
| 86803 | <1% | 514 | $235.34 | |
| 80050 | General health panel | <1% | 193 | $188.06 |
| 83540 | <1% | 1,169 | $169.80 | |
| 87186 | <1% | 562 | $141.78 | |
| 82043 | <1% | 2,399 | $133.62 | |
| 87088 | <1% | 576 | $122.24 | |
| 85610 | <1% | 911 | $111.87 | |
| 86140 | <1% | 464 | $107.11 | |
| 81003 | <1% | 1,090 | $103.95 | |
| 83735 | <1% | 906 | $100.49 | |
| 84154 | <1% | 329 | $98.34 | |
| 83550 | <1% | 990 | $96.89 | |
| 80055 | <1% | 36 | $95.50 | |
| 87081 | <1% | 80 | $93.34 | |
| 82375 | <1% | 14 | $82.52 | |
| 81244 | <1% | 18 | $78.48 | |
| 84702 | <1% | 166 | $74.19 | |
| 85730 | <1% | 704 | $63.13 | |
| 82947 | <1% | 266 | $52.33 | |
| 80074 | <1% | 465 | $48.11 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 524 | $47.57 |
| 82784 | <1% | 56 | $44.31 | |
| 82570 | <1% | 2,191 | $43.58 | |
| 82670 | <1% | 74 | $38.78 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 342 | $35.75 |
| 86200 | <1% | 15 | $24.43 | |
| 84146 | <1% | 16 | $23.09 | |
| 86431 | <1% | 220 | $21.61 | |
| 86235 | <1% | 13 | $14.01 | |
| 87077 | <1% | 246 | $11.73 | |
| 83001 | <1% | 27 | $9.62 | |
| 83002 | <1% | 59 | $9.59 | |
| 83516 | <1% | 16 | $9.01 | |
| 82677 | <1% | 112 | $5.69 | |
| 82950 | <1% | 27 | $3.85 | |
| 86336 | <1% | 112 | $3.68 | |
| 81001 | <1% | 2,966 | $2.84 | |
| 85014 | <1% | 16 | $1.92 | |
| 85018 | <1% | 15 | $1.92 | |
| 82248 | 0% | 381 | $0.00 | |
| 87999 | 0% | 172 | $0.00 | |
| 83970 | 0% | 317 | $0.00 | |
| 82274 | 0% | 299 | $0.00 | |
| 84550 | 0% | 1,086 | $0.00 | |
| 84450 | 0% | 70 | $0.00 | |
| 84100 | 0% | 569 | $0.00 | |
| 87535 | 0% | 15 | $0.00 | |
| 86900 | 0% | 12 | $0.00 | |
| 87338 | 0% | 28 | $0.00 | |
| 84156 | 0% | 174 | $0.00 | |
| 82565 | 0% | 321 | $0.00 | |
| 82310 | 0% | 131 | $0.00 | |
| 84481 | 0% | 389 | $0.00 | |
| 84403 | 0% | 402 | $0.00 | |
| 83695 | 0% | 25 | $0.00 | |
| 80076 | 0% | 36 | $0.00 | |
| 84295 | 0% | 95 | $0.00 | |
| 84155 | 0% | 80 | $0.00 | |
| 84520 | 0% | 186 | $0.00 | |
| 82977 | 0% | 94 | $0.00 | |
| 82247 | 0% | 78 | $0.00 | |
| 82627 | 0% | 12 | $0.00 | |
| 84305 | 0% | 12 | $0.00 | |
| 87150 | 0% | 14 | $0.00 | |
| 83655 | 0% | 25 | $0.00 | |
| 82652 | 0% | 12 | $0.00 | |
| 84165 | 0% | 14 | $0.00 | |
| 86696 | 0% | 15 | $0.00 | |
| 87340 | 0% | 533 | $0.00 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 403 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 275 | $0.00 |
| 84153 | 0% | 1,359 | $0.00 | |
| 86704 | 0% | 291 | $0.00 | |
| 86592 | 0% | 1,021 | $0.00 | |
| 84075 | 0% | 56 | $0.00 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 0% | 322 | $0.00 |
| 84436 | 0% | 576 | $0.00 | |
| 86706 | 0% | 315 | $0.00 | |
| 83880 | 0% | 213 | $0.00 | |
| 83615 | 0% | 238 | $0.00 | |
| 86376 | 0% | 54 | $0.00 | |
| 84480 | 0% | 96 | $0.00 | |
| 84402 | 0% | 116 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 0% | 32 | $0.00 |
| 84479 | 0% | 207 | $0.00 | |
| 82040 | 0% | 77 | $0.00 | |
| 82435 | 0% | 125 | $0.00 | |
| 84132 | 0% | 80 | $0.00 | |
| 86225 | 0% | 14 | $0.00 | |
| 82533 | 0% | 12 | $0.00 | |
| 86695 | 0% | 13 | $0.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 12 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 69 | $0.00 |
| 86141 | 0% | 13 | $0.00 | |
| 86701 | 0% | 13 | $0.00 | |
| 83090 | 0% | 12 | $0.00 | |
| 80051 | 0% | 14 | $0.00 | |
| 88141 | 0% | 40 | $0.00 | |
| 87070 | 0% | 12 | $0.00 | |
| 87529 | 0% | 13 | $0.00 | |
| 86702 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KIMBERLY (VP)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.